Back to Journals » Therapeutics and Clinical Risk Management » Volume 5

Tenofovir and its potential in the treatment of hepatitis B virus

Authors Reynaud L, Carleo M, Talamo M, Borgia G

Published 2 February 2009 Volume 2009:5 Pages 177—185

DOI https://doi.org/10.2147/TCRM.S3335

Review by Single-blind

Peer reviewer comments 4

Laura Reynaud, Maria Aurora Carleo, Maria Talamo, Guglielmo Borgia

Department of Public Medicine and Social Security – Section of Infectious Disease University of Naples “Federico II”, Italy

Abstract: Recent literature is reviewed about treatment of chronic hepatitis B virus (CHB), focusing on tenofovir disoproxil fumarate (TDF; Viread®), among the nucleotide and nucleoside analogs. TDF pharmacokinetics and pharmacodynamics, activity in respect of hepatitis B virus (HBV) multi-drug-resistant mutations, efficacy in treatment-naïve and treatment-experienced patients, and side effects are described. The most predictive response factors to TDF therapy are discussed and all available combination therapies to optimize clinical outcome in the various patient profiles are analyzed, such as compensated and/or decompensated cirrhotic patients. The use of TDF in pregnancy, and prophylaxis after exposure to HBV and post-liver transplantation are also evaluated.

Keywords: HBV, chronic hepatitis B, tenofovir, antiviral therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]